Celyad Oncology (LTS:0QFK) Common Stock : €78.59 Mil (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Common Stock?

Celyad Oncology's quarterly common stock stayed the same from Jun. 2022 (€78.59 Mil) to Dec. 2022 (€78.59 Mil) and stayed the same from Dec. 2022 (€78.59 Mil) to Jun. 2023 (€78.59 Mil).

Celyad Oncology's annual common stock increased from Dec. 2020 (€48.51 Mil) to Dec. 2021 (€78.59 Mil) but then stayed the same from Dec. 2021 (€78.59 Mil) to Dec. 2022 (€78.59 Mil).

Celyad Oncology Common Stock Historical Data

The historical data trend for Celyad Oncology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Common Stock Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

41.55

48.51

78.59

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Common Stock	Get a 7-Day Free Trial															78.59	78.59	78.59	78.59	78.59

Celyad Oncology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Celyad Oncology (LTS:0QFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (LTS:0QFK) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (LTS:0QFK) Headlines

No Headlines